Movement Alert｜Tango Therapeutics Inc. Falls 12.1% in Regular Trading, Early Pancreatic Cancer Data Trigger Market Split

Market Focus10-24

On October 24, Tango Therapeutics Inc. fell 12.1% in regular trading, trading at $24.555/share, with turnover of $254 million.

The move followed updated phase 1/2 data for the company’s vopimetostat-daraxonrasib combination in previously treated pancreatic cancer, where strong efficacy metrics were offset by notable treatment-related toxicity, contributing to a divided market response.

Among 22 evaluable patients, the study reported an 82% objective response rate, 100% disease control, and an 88% nine-month progression-free survival rate, with median progression-free survival not yet reached. However, 40% of safety-evaluable patients experienced grade 3 treatment-related adverse events. The company also said it plans to start a global randomized phase 3 trial in the first half of next year for MTAP-deleted pancreatic cancer, but the early-stage nature of the dataset and safety profile appear to have tempered investor enthusiasm.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment